Nonmyeloablative bone marrow transplantation is effective in the treatment of autoimmune diseases and hemoglobinopathies. [1] [2] [3] [4] Diamond-Blackfan anemia (DBA) is a childhood disorder characterized by normochromic-macrocytic anemia, reticulocytopenia and normocellular bone marrow with a selective deficiency of erythroid progenitors. 5 Most patients initially respond to corticosteroids, but about 60% of patients require chronic red cell transfusions and die from hemosiderosis in the second or third decade of life. Allogeneic bone marrow transplantation (BMT) is an effective therapy for steroid-resistant, transfusion-dependent DBA with survival rates of 60-80% in patients transplanted from HLA-matched related donors. 6, 7 A conditioning regimen based on fludarabine and low-dose TBI (2 Gy) permits engraftment and full donor chimerism in both malignant and nonmalignant diseases, and can potentially avoid complications such as retarded growth and development, cataract formation and sterility in children. 2, 8 We chose this regimen for a transfusion-dependent, 19-month-old boy with DBA.
The child was found to have severe anemia on day 4 of life. The birth weight was 1700 g, and the pregnancy was uncomplicated. Physical examination showed short stature, cleft palate and abnormal implantation of the first chirodactile. The hemoglobin was 4 g/dl, the total white blood cell count 4.8 Â 10 9 /l, the differential count normal, the platelet count 300 Â 10 9 /l and the reticulocyte count 0.1%. The karyotype was normal (46XY) and he was DEB negative. At the age of 5 months, bone marrow showed marked erythroid hypoplasia with no abnormal cells, confirming the diagnosis of DBA. The parents were healthy and there was no evidence of consanguinity. He initially received an average of three red cell transfusions per month.
In January 2003, he underwent allogeneic BMT, with his healthy 3-year-old HLA-identical sister as donor. By then, he had received a total of 26 units of packed red cells, without iron-chelating therapy (as is frequently the case in developing countries) and was steroid resistant. Owing to his chronic corticosteroid exposure and heavy transfusion history, his parents agreed to nonmyeloablative conditioning (2 Gy TBI plus 90 mg/m 2 fludarabine). GVHD prophylaxis included cyclosporine (6 mg/kg/day) and methotrexate on days 1, 3, 6 and 11. The graft contained 3.8 Â 10 6 CD34 þ cells/kg recipient weight. He was isolated in a private room in the ICU and received broad-spectrum antibiotics during the neutropenic phase, which lasted 3 days and did not necessitate transfusion. The post transplant course was uneventful.
With a follow-up of 10 months, no signs of toxicity or GVHD have been observed, and his current performance status is 100%. Hemoglobin and reticulocyte levels are normal. Full donor chimerism was confirmed by peripheral blood karyotype on days 30, 60, 120 and 180. He has received no transfusions since conditioning started. Bone marrow examination 8 months after transplantation showed 23% erythroid precursors.
Nonmyeloablative BMT can offer better short-and long-term quality of life than standard BMT with high-dose chemoradiotherapy-based conditioning, and is also less expensive, making it particularly suitable for developing countries. Nonmyeloablative BMT is likely to be safer in terms of long-term outcome and complications, although this remains to be demonstrated. 2, 8 Our experience suggests that this approach is a safe alternative method for achieving hematopoietic chimerism in selected patients with DBA. 
